In final guidance which rubber-stamps an earlier decision, the National Institute for Health and Care Excellence (Nice) said olaparib (also called Lynparza) is not a good use of NHS money at its current price. The Independent
Thursday, 8 September 2022
Life-extending prostate cancer drug rejected for NHS
Life-extending prostate cancer drug rejected for NHS A drug which can extend the lives of some men with prostate cancer will not be approved for use on the NHS.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment